


سامية محمد مصطفى



شبكة المعلومات الجامعية

بسم الله الرحمن الرحيم




سامية محمد مصطفى



شبكة المعلومات الجامعية



شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم



سامية محمد مصطفى



شبكة المعلومات الجامعية

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم


قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار




سامية محمد مصطفى



شبكة المعلومات الجامعية



بعض الوثائق الأصلية تالفة




سامية محمد مصطفى



شبكة المعلومات الجامعية



بالرسالة صفحات لم ترد بالأصل



Assessment of Dual Blockade of the Renin-Angiotensin System in Patients with Type II Diabetic Nephropathy

A Thesis
Submitted for the partial fulfillment
of Master Degree in Pharmaceutical Sciences
(*Clinical Pharmacy*)

By
Gehad Abdul Rahman El Nakeeb (B.Sc)

Supervisors

Dr. Mohsen A. Hedaya

Associate Professor
of Clinical Pharmacy,
Faculty of Pharmacy,
Tanta University

Dr. Mohammed Y. Abdel Aziz

Associate Professor
of Internal Medicine,
Faculty of Medicine,
Mansoura University

Clinical Pharmacy Department
Faculty of Pharmacy
Tanta University
2006

B

150 CV

**Assessment of Dual Blockade
of the Renin-Angiotensin System
in Patients with Type II Diabetic Nephropathy**

A Thesis
Submitted for the partial fulfillment
of Master Degree in Pharmaceutical Sciences
(*Clinical Pharmacy*)

By
Gehad Abdul Rahman El Nakeeb (B.Sc)

Supervisors

Dr. Mohsen A. Hedaya

Associate Professor
of Clinical Pharmacy,
Faculty of Pharmacy,
Tanta University

Dr. Mohammed Y. Abdel Aziz

Associate Professor
of Internal Medicine,
Faculty of Medicine,
Mansoura University

Clinical Pharmacy Department
Faculty of Pharmacy
Tanta University
2006

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالُوا سُبْحَانَكَ اللَّهُ عَمَّا يُشْرِكُونَ
عَلِمْتَ إِنْ أَنْتَ إِلَّا عَلِيمٌ الْحَكِيمُ

قُلْ هُوَ اللَّهُ أَحَدٌ

البقرة آية: (٣٢)


APPROVAL SHEET

Approved by:

Committee in charge:

Signature


1- Prof. Dr. Wageh Mahmoud Awara



Professor of Pharmacology

Faculty of Pharmacy, Tanta University


2- Prof. Dr. Osama Ahmed Badary



Professor of Pharmacology

Faculty of Pharmacy, Helwan University

3- Prof. Dr. Mohsen Abdel-Fattah Hedaya



Associate Professor of Clinical Pharmacy

Faculty of Pharmacy, Tanta University

Data: March 28, 2006

Acknowledgments

I am deeply indebted to my supervisor Prof. Dr. Mohsen A. Hedaya, Associate Professor of Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, whose sincere guidance, valuable instructions, and immense assistance have remarkable influence throughout the entire time of the work and of writing the thesis.

My grateful and sincere thanks are due to Prof. Dr. Mohammed Y. Abdel Aziz, Associate Professor of Internal Medicine Department, Faculty of Medicine, Mansoura University, for his constant encouragement and support and for his kind help during the accomplishment of this work.

I would like to express my great thanks and appreciation to Dr. Saher K. Hegazy, Lecturer of Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, for her revision of the thesis.

I wish to extend my warm thanks to all staff members of the endocrinology department, Specialized Internal Medicine Hospital, Mansoura University, for their help and cooperation.

Table of Contents

	Page No
List of Abbreviations	v
List of Tables	vii
List of figures	ix
Abstract	1
Introduction	3
1 An overview of diabetic nephropathy.....	3
1.1 Prevalence	3
1-2 Risk factors.....	4
1-2-1 Susceptibility factors	4
1-2-2 Progression factors	5
1-3 Pathology	6
1-4 Comorbid associations	7
1-4-1 Retinopathy	7
1-4-2 Peripheral and autonomic neuropathy	7
1-4-3 Cardiovascular disease	7
2 Screening and diagnosis	8
2-1 Assessment of proteinuria	8
2-2 Glomerular filtration rate	10
2-3 Markers of chronic kidney disease other than proteinuria	12
3 Pathogenesis	14
3-1-1 Metabolic factors	14
Polyol pathway	14
Advanced glycosylation end (AGE) precursors	15
Protein kinase-C (PKC) activation	15
Increased hexosamine pathway activity	16
The unified mechanism theory/ Reactive oxygen intermediate pathway	16
3-1-2 Hemodynamic factors	19
Renin angiotensin system (RAS)	19
Endothelin	22

Nitric oxide (NO)	22
3-1-3 Growth factors	23
Transforming growth factor β (TGF- β)	23
Growth hormone (GH) and insulin like growth factors (IGFs)	24
Vascular endothelial growth factor (VEGF)	24
Platelet derived growth factor (PDGF)	25
3-2 Functional/ physiologic aspects	25
4 Diabetic nephropathy and TGF- β	26
5 Primary prevention (prevention of microalbuminuria development)	30
5-1 Intensive blood glucose control	30
5-2 Intensive blood pressure control	31
5-3 Renin angiotensin system	32
6 Treatment (secondary and tertiary prevention= prevention of macroalbuminuria and ESRD) With emphasis on RAS	33
6-1 Intensive blood glucose control	33
6-2 Renin angiotensin system	34
6-2-1 Microalbuminuria patients	34
[A] Type 1 diabetes	34
Angiotensin II receptor blockers	34
Angiotensin converting enzyme inhibitors	34
[B] Type 2 diabetes	35
Angiotensin II receptor blockers	35
Angiotensin converting enzyme inhibitors	37
6-2-2 Macroalbuminuria patients	37
[A] Type 1 diabetes	37
Angiotensin II receptor blockers	37
Angiotensin converting enzyme inhibitors	37
[B] Type 2 diabetes	38
Angiotensin II receptor blockers	38
Angiotensin converting enzyme inhibitors	40
6-2-3 Side effects	42
6-2-4 Aspects related to AIIRB	43
The antiproteinuric effect	43

Kidney function	44
Renoprotective dose	44
Time course of antiproteinuric effect	45
Cost effectiveness	46
6-2-5 ACE insertion deletion polymorphism	46
6-2-6 RAS effects other than renoprotection	47
Cardiological significance	47
Prevention of diabetes	50
6-2-7 Dual blockade of the RAS	52
Rationale	52
Type 2 diabetes	53
Type 1 diabetes	56
Non diabetic nephropathy	57
6-3 Tight blood pressure control	58
6-4 Other approaches implemented in diabetic nephropathy management	62
6-4-1 Diet intervention	62
Protein restriction	62
Phosphorous restriction	62
Salt restriction	62
6-4-2 Smoking cessation	63
6-4-3 Dyslipidemia management	63
6-4-4 Anemia management	63
6-4-5 Use of aspirin	64
6-4-6 Aldosterone blockade	64
6-4-7 Multifactorial intervention	64
6-4-8 Nephrologist referral	65

Aim of the Work	66
Subjects and Methods	67
Results	87
Discussion	120
Conclusions	127
References	128
Arabic Summary	149

List of Abbreviations

AI	Angiotensin I
AII	Angiotensin II
ACE	Angiotensin converting enzyme
ACE-I	Angiotensin converting enzyme inhibitor
ADA	American diabetes association
AGE	Advanced glycosylation end products
ALLHAT	The antihypertensive and lipid lowering treatment to prevent heart attack trial
AR	Aldose reductase
AIIRB	Angiotensin II receptor blocker
AT1	Angiotensin II type 1 receptor
AT2	Angiotensin II type 2 receptor
BENEDICT	Bergamo nephrologic diabetes complication trial
BP	Blood pressure
CALM	The candesartan and lisinopril microalbuminuria study
CARDS	The collaborative atrovastatin diabetes study
CCB	Calcium channel blocker
CKD	Chronic kidney disease
DCCT	Diabetes control and complication trial
CHARM	Candesartan in heart failure- assessment of reduction in mortality and morbidity program
CTGF	Connective tissue growth factor
CV	Cardiovascular
DN	Diabetic nephropathy
ECM	Extracellular matrix
ESRD	End stage renal disease
ETs	Endothelins
ET-1	Endothelin-1
GFAT	Glutamine fructose-6 phosphate amidotransferase
GFR	Glomerular filtration rate
GH	Growth hormone
HbA1c	Glycosylated haemoglobin